InBrain Pharma Shares Exciting Results from DIVE-I Trial
InBrain Pharma, a prominent biopharmaceutical company focused on neurodegenerative conditions, is drawing attention with the encouraging outcomes from its DIVE-I clinical trial, which targets the complexities of Parkinson’s disease. Taking place in Philadelphia, this event is a significant milestone for the company as it reveals its groundbreaking results to the scientific world.
DIVE-I Clinical Trial Overview at an Esteemed Event
The DIVE-I trial will be showcased at the upcoming International Congress of Parkinson’s Disease and Movement Disorders. It emphasizes the effectiveness of a new device-assisted therapy aimed at individuals who are severely affected by advanced-stage Parkinson's disease. This cutting-edge therapy offers an alternative approach by delivering dopamine directly into the brain, addressing severe motor symptoms caused by the progression of the disease and the limitations of current oral medications.
Trial Highlights
Professor David Devos, a neurologist and pharmacologist at Lille University and co-founder of InBrain Pharma, expressed his optimism about the trial's outcomes. The study included 12 patients who received treatment with A-dopamine, compared to a conventional optimized oral regimen. The findings showed not just a positive safety profile but also a noteworthy reduction in motor symptoms like difficulty walking, involuntary movements, and agitation. Impressively, every patient who participated in the treatment chose to continue, underscoring its potential significance.
Insights from the CEO
Dr. Véronique Foutel, the CEO of InBrain Pharma, highlighted the importance of these advancements, especially for patients who currently have limited choices for managing advanced Parkinson’s disease. She expressed eagerness to engage with regulatory agencies to discuss the next steps in clinical development.
A Closer Look at the DIVE-I Trial
Initiated in 2020, the DIVE-I trial was carefully structured as a multi-phase study, incorporating feasibility, efficacy, and follow-up segments. It focused on patients dealing with motor complications, particularly those experiencing freezing and dyskinesia. Each participant had a precision dosing pump implanted that delivered dopamine directly to the third ventricle of the brain, reducing side effects typically associated with conventional treatments.
Trial Structure Explained
The trial evolved from a randomized single-group design to a two-arm crossover format in its later stages. This adjustment aimed to assess the comparative efficacy of the treatments. Over two months, patients alternated between receiving either a placebo or the active dopamine treatment, ensuring a thorough examination of the therapy's benefits while still using their optimized oral medications.
Safety and Effectiveness Metrics
The primary focus was on measuring patients' control over motor symptoms during daily activities. Secondary assessments evaluated fluctuations in motor functioning and overall quality of life using standardized measures like the Dyskinesia Rating Score and the MDS-UPDRS. Additionally, neuropsychological evaluations were conducted to provide a comprehensive view of patient health.
InBrain Pharma's Broader Commitment
Founded in 2018, InBrain Pharma is committed to pioneering new treatments for Parkinson's disease, drawing on research from renowned scientists at the University of Lille. With notable recognitions, including accolades from the European Inventor Award, the company stands at the forefront of advancements in neurological therapies.
The Growing Challenge of Parkinson's Disease
Parkinson's disease is considered one of the fastest-growing neurological disorders worldwide, with a significant rise in cases seen over the past few decades. Current therapies frequently leave advanced-stage patients with inadequate options. InBrain Pharma’s innovative method of dopamine infusion has the potential to bridge this critical gap in effective treatment.
Frequently Asked Questions
What were the results of the DIVE-I clinical trial?
The DIVE-I clinical trial reported encouraging safety and efficacy findings, with noteworthy improvements in the management of severe motor symptoms among participants.
Who is Professor David Devos?
Professor David Devos is a neurologist and pharmacologist at Lille University who specializes in Parkinson’s disease research and is a co-founder of InBrain Pharma.
What treatment approach does InBrain Pharma use?
InBrain Pharma employs device-assisted therapy that delivers dopamine directly to the brain, specifically targeting severe motor symptoms related to Parkinson’s disease.
What sets the DIVE-I trial apart?
The DIVE-I trial stands out due to its unique method of combining direct dopamine administration with a structured assessment of treatment efficacy and safety for patients with advanced Parkinson's disease.
What does the future hold for InBrain Pharma's research?
InBrain Pharma intends to advance its promising findings through collaborations with global experts and discussions with regulatory bodies to improve treatment options for those living with Parkinson’s disease.
